secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cyclerion Therapeutics, Inc. (CYCN)
CIK:        0001755237
Form:       8-K
Filed at:   2023-12-04T23:59:59+00:00
Accession:  0001193125-23-288498
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cyclerion appoints Regina Graul as President; CEO Peter Hecht transitions to strategic consultant
--------------------------------------------------------------------------------

- Regina Graul, Ph.D., appointed President effective Dec 1, 2023; CEO Peter Hecht steps down but remains strategic consultant and board member.
- Graul earns $372K base salary, bonuses up to $125K, and up to 100K restricted shares vesting over time.
- Graul previously VP at EQRx and olinciguat program lead at Cyclerion; 15+ years at Ironwood Pharmaceuticals.
- Hecht completed transitional assignment; Cyclerion to rebuild with board additions Dina Katabi and Michael Higgins.
- Company to evaluate existing assets and pursue external innovation for next phase.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1755237/000119312523288498/0001193125-23-288498-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1755237/000119312523288498/d569286d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-288498

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer